secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0000950170-24-113091
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto acquires global rights to BRM-1420 dual ENL-YEATS/FLT3 inhibitor for AML
--------------------------------------------------------------------------------

- Galecto issued 62,594 common shares and 160.562 Series A convertible preferred shares (convertible into 160,562 common) to Bridge Medicines.
- BRM-1420 is a novel dual ENL-YEATS and FLT3 inhibitor targeting multiple genetic subsets of acute myeloid leukemia (AML).
- Carl Goldfischer, Galecto's Chairman, also serves as Executive Chairman of Bridge Medicines (related-party transaction).
- Pro forma impact: cash reduced by $2.68M; total consideration valued at stock issuance; assumes liabilities.
- Stockholder approval required for conversion of preferred shares; Bridge Medicines restricted from selling shares for 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017024113091/0000950170-24-113091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017024113091/glto-20241007.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer